Skip to main content
. 2014 Nov 26;6(2):651–661. doi: 10.18632/oncotarget.2892

Figure 4. Targeting GLUT1, either in vitro or in vivo, effectively inhibits tumor initiation by CSCs.

Figure 4

(A) Mice (3 for each group) were implanted subcutaneously with the indicated numbers of viable PANC-1 CSLCs that had been treated without (Control) or with 10 μM WZB117 for 6 days. (B) Mice implanted subcutaneously with the indicated numbers of viable PANC-1 CSLCs (3 for each group) were administered a daily intraperitoneal injection of the control vehicle or WZB117 (20 mg/kg/day) for 10 consecutive days starting on the next day of implantation.(C) Mice (4 for each group) were implanted subcutaneously with PANC-1 CSLCs. After 30 days, when the tumor volumes ranged from 292 to 1080 mm3, the mice were randomized and received a daily intraperitoneal injection of the control vehicle or WZB117 (20 mg/kg/day) for 10 consecutive days. In (A) through (C), tumor volume was measured at the indicated time points after implantation, and the results are presented in the graphs as means + SD of each group. *p<0.05 (WZB117 5 × 105 compared against Control 5 × 105 in (A) and (B)).